Drug Profile
Odronextamab - Regeneron Pharmaceuticals
Alternative Names: CD20xCD3 bispecific antibody - Regeneron Pharmaceuticals; REGN-1979; ZL-1307Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Developer Regeneron Pharmaceuticals; ZAI Lab
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Diffuse large B cell lymphoma; Follicular lymphoma
- Phase III Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Phase I B-cell lymphoma; Chronic lymphocytic leukaemia
Most Recent Events
- 25 Mar 2024 Odronextamab - Regeneron Pharmaceuticals receives Orphan Drug status for Follicular lymphoma in European Union
- 25 Mar 2024 US FDA issues complete response letters for BLA of odronextamab for Follicular lymphoma and Diffuse large B cell lymphoma
- 15 Feb 2024 Phase-III clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in Australia, Italy (IV) (NCT06230224)